

# Matthew J Sikora

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8577193/publications.pdf>

Version: 2024-02-01

34  
papers

1,197  
citations

430442

18  
h-index

414034

32  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2025  
citing authors

#	ARTICLE	IF	CITATIONS
1	Unlocking the Mysteries of Lobular Breast Cancer Biology Needs the Right Combination of Preclinical Models. <i>Molecular Cancer Research</i> , 2022, 20, 837-840.	1.5	3
2	Mutual exclusivity of ESR1 and TP53 mutations in endocrine resistant metastatic breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 62.	2.3	10
3	Making an IMPACT on Career Development for Early- and Mid-career Faculty. <i>Endocrinology</i> , 2021, 162, .	1.4	0
4	WNT4 Balances Development vs Disease in Gynecologic Tissues and Women's Health. <i>Endocrinology</i> , 2021, 162, .	1.4	10
5	Mediator of DNA Damage Checkpoint 1 (MDC1) Is a Novel Estrogen Receptor Coregulator in Invasive Lobular Carcinoma of the Breast. <i>Molecular Cancer Research</i> , 2021, 19, 1270-1282.	1.5	9
6	Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4. <i>Cancers</i> , 2020, 12, 2931.	1.7	20
7	The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval. <i>Clinical Cancer Research</i> , 2020, 26, 6362-6373.	3.2	32
8	Differential Regulation and Targeting of Estrogen Receptor $\beta$ Turnover in Invasive Lobular Breast Carcinoma. <i>Endocrinology</i> , 2020, 161, .	1.4	17
9	OR12-05 MDC1 Is a Novel Estrogen Receptor Co-Regulator in Invasive Lobular Carcinoma of the Breast. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.1	0
10	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. <i>Npj Breast Cancer</i> , 2019, 5, 19.	2.3	46
11	Activation of Wnt signaling promotes olaparib resistant ovarian cancer. <i>Molecular Carcinogenesis</i> , 2019, 58, 1770-1782.	1.3	68
12	Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinoma. <i>Cancer Letters</i> , 2019, 461, 21-30.	3.2	18
13	SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 327-337.	1.1	12
14	Wnt family member 4 (WNT4) and WNT3A activate cell-autonomous Wnt signaling independent of porcupine O-acyltransferase or Wnt secretion. <i>Journal of Biological Chemistry</i> , 2019, 294, 19950-19966.	1.6	31
15	The Evolution of Estrogen Receptor Signaling in the Progression of Endometriosis to Endometriosis-Associated Ovarian Cancer. <i>Hormones and Cancer</i> , 2018, 9, 399-407.	4.9	6
16	Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer. <i>Breast Cancer Research</i> , 2018, 20, 106.	2.2	69
17	Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. <i>Cancer Research</i> , 2018, 78, 6209-6222.	0.4	58
18	Active Estrogen Receptor-alpha Signaling in Ovarian Cancer Models and Clinical Specimens. <i>Clinical Cancer Research</i> , 2017, 23, 3802-3812.	3.2	43

#	ARTICLE	IF	CITATIONS
19	CRISPR Fish Reel in Novel Roles for Estrogen Receptors in Reproduction. <i>Endocrinology</i> , 2017, 158, 2082-2083.	1.4	2
20	Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistance. <i>Nature Communications</i> , 2017, 8, 1865.	5.8	108
21	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype. <i>Clinical Cancer Research</i> , 2016, 22, 5068-5078.	3.2	38
22	The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 23-30.	1.1	10
23	Endocrine Response Phenotypes Are Altered by Charcoal-Stripped Serum Variability. <i>Endocrinology</i> , 2016, 157, 3760-3766.	1.4	50
24	Family Matters: Collaboration and Conflict Among the Steroid Receptors Raises a Need for Group Therapy. <i>Endocrinology</i> , 2016, 157, 4553-4560.	1.4	15
25	WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. <i>Breast Cancer Research</i> , 2016, 18, 92.	2.2	56
26	High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome. <i>Gynecologic Oncology</i> , 2016, 141, 348-356.	0.6	20
27	Invasive Lobular Carcinoma Cell Lines Are Characterized by Unique Estrogen-Mediated Gene Expression Patterns and Altered Tamoxifen Response. <i>Cancer Research</i> , 2014, 74, 1463-1474.	0.4	122
28	Invasive lobular carcinoma of the breast: Patient response to systemic endocrine therapy and hormone response in model systems. <i>Steroids</i> , 2013, 78, 568-575.	0.8	41
29	Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 1027-1039.	1.1	26
30	Reliable Gene Expression Measurements from Fine Needle Aspirates of Pancreatic Tumors. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 566-575.	1.2	5
31	The androgen metabolite 5 $\alpha$ -androstane-3 $\beta$ ,17 $\beta$ -diol (3 $\beta$ -Adiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 289-296.	1.1	74
32	Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 571-575.	1.1	63
33	Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol. <i>Cancer Biology and Therapy</i> , 2008, 7, 767-776.	1.5	17
34	The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 538-545.	1.3	89